Tocilizumab versus the Covid19 tempest: All's well that ends well or much ado about nothing?

Clin Microbiol Infect. 2021 Feb;27(2):158-159. doi: 10.1016/j.cmi.2020.09.033. Epub 2020 Sep 29.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • COVID-19 Drug Treatment*
  • Humans
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • tocilizumab